Cancer
Malignant Pancreatic Neoplasm
CI-CAN-00001159Explore in graph →
Top-level904 active trials8 approved drugs63 evidence items
- NCIt
- C9005
- ICD-10
- C25
- DOID
- 1793
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001159Explore in graph →
Clinical trials
3,630 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (516)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06370754 | Newly Emerging Immunotherapy for Pancreatic Cancer Treatment(FD-IMPACT) | not yet recruiting | Phase 1 / Phase 2 | 117 | Fudan UniversityOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06111274 | A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer | recruiting | Phase 2 | 82 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Apr 11, 2024 | clinicaltrials |
| NCT06361030 | Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer | not yet recruiting | Phase 2 | 40 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT06353581 | Prophylactic Administration of Neulapeg (Pegteograstim) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Receiving the Modified FOLFIRINOX | unknown | Phase 2 | 78 | Yonsei UniversityOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT05064618 | Investigator-initiated Clinical Trial of MIKE-1(MIKE-1) | unknown | Phase 1 / Phase 2 | 55 | Nagoya UniversityOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT05984810 | NIR-Fluorescence Guided Surgical Resection of Neoadjuvant Treated Localized Pancreatic Cancer Using SGM-101(FLUOPANC-II) | recruiting | Phase 2 | 20 | Leiden University Medical CenterOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT03721744 | A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer | unknown | Phase 2 / Phase 3 | 336 | 1Globe Health Institute LLCINDUSTRY | 3 | Apr 3, 2024 | clinicaltrials |
| NCT06345300 | NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study | unknown | Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06145074 | Examining Safety, Efficacy and Feasibility of Preoperative Propranolol in Patients With PDAC.(IMPULS) | recruiting | Phase 2 | 30 | Zealand University HospitalOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT05048524 | Peri-operative SLOG for Localized Pancreatic Cancer | unknown | Phase 2 | 64 | National Health Research Institutes, TaiwanOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06196788 | Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer(PTCA199-9) | recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT04431258 | ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study(PanC-ASAP) | completed | Phase 1 / Phase 2 | 150 | Ability Pharmaceuticals SLINDUSTRY | 4 | Mar 18, 2024 | clinicaltrials |
| NCT06259058 | Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer | not yet recruiting | Phase 1 / Phase 2 | 96 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Mar 15, 2024 | clinicaltrials |
| NCT04617067 | Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer | completed | Phase 2 | 15 | Cancer Trials IrelandNETWORK | 1 | Mar 6, 2024 | clinicaltrials |
| NCT06233877 | Clinical Trial Evaluating Low Dose G-FLIP Plus Mitomycin C for Stage IV Pancreatic Cancer(GFLIPM) | not yet recruiting | Phase 2 | 60 | Hirschfeld OncologyOTHER_GOV | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06278493 | A Clinical Study of AL2846 Capsule Combined With Gemzar Injection in the Treatment of Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 34 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Feb 26, 2024 | clinicaltrials |
| NCT04177810 | Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer | completed | Phase 2 | 25 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT06151262 | A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer | recruiting | Phase 2 | 30 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT06255912 | Clinical Trial for Advanced or Metastatic Pancreatic Cancer | not yet recruiting | Phase 2 | 26 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Feb 23, 2024 | clinicaltrials |
| NCT03924466 | Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients(VUBAR) | unknown | Phase 2 | 55 | Universitair Ziekenhuis BrusselOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT05988814 | Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy(FOLFIRINOX3 P) | recruiting | Phase 2 | 90 | Centre Georges Francois LeclercOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT01959139 | S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 126 | SWOG Cancer Research NetworkNETWORK | 1 | Feb 9, 2024 | clinicaltrials |
| NCT06245330 | A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 180 | Ascentawits Pharmaceuticals, LtdINDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT01525082 | Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 20 | Shaheen ShaguftaOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT03376659 | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 8 | Georgetown UniversityOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT06234072 | Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients | not yet recruiting | Phase 2 | 120 | Shenzhen University General HospitalOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT05074472 | A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors | completed | Phase 1 / Phase 2 | 35 | ZielBio, Inc.INDUSTRY | 1 | Jan 29, 2024 | clinicaltrials |
| NCT06229340 | Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations(NТО-RAS) | recruiting | Phase 2 | 20 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | Jan 29, 2024 | clinicaltrials |
| NCT06202014 | Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in LAPC | unknown | Phase 2 | 43 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 19, 2024 | clinicaltrials |
| NCT06210360 | Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX | not yet recruiting | Phase 2 | 134 | Changhai HospitalOTHER | 0 | Jan 18, 2024 | clinicaltrials |
| NCT04617457 | Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas(HOLIPANC) | unknown | Phase 2 | 150 | University of CologneOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT04624217 | A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer | completed | Phase 1 / Phase 2 | 56 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 11, 2024 | clinicaltrials |
| NCT05955157 | Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma | unknown | Phase 2 / Phase 3 | 52 | University of MalayaOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT04889742 | Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors(HETERERO) | not yet recruiting | Phase 2 | 110 | Charite University, Berlin, GermanyOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT03340974 | Pilot Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in Combination With GC4419 in Pancreatic Cancer | completed | Phase 1 / Phase 2 | 42 | Galera Therapeutics, Inc.INDUSTRY | 1 | Dec 15, 2023 | clinicaltrials |
| NCT06172036 | Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab(CAPT-02) | not yet recruiting | Phase 2 | 180 | Zhejiang UniversityOTHER | 0 | Dec 15, 2023 | clinicaltrials |
| NCT06172634 | A Single-center Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow-derived DCs(CellgramDC-WT1) and Immune Checkpoint Inhibitors in Patients With Metastatic Pancreatic Cancer Who Have Failed First-line or More Standard Chemotherapy(DICI_PC) | unknown | Phase 1 / Phase 2 | 10 | Soonchunhyang University HospitalOTHER | 0 | Dec 15, 2023 | clinicaltrials |
| NCT06159478 | Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)(Perfume) | recruiting | Phase 2 | 32 | National Cancer Center, JapanOTHER_GOV | 1 | Dec 13, 2023 | clinicaltrials |
| NCT06168552 | Fluorescent Navigation Technology in Radical Resection of Pancreatic Cancer(CISPD-6) | unknown | Phase 1 / Phase 2 | 20 | Zhejiang UniversityOTHER | 0 | Dec 13, 2023 | clinicaltrials |
| NCT06153368 | Cadonilimab Plus mFOLFIRINOX as Conversion Therapy in LAPC | unknown | Phase 2 | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT03189914 | RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 46 | Processa PharmaceuticalsINDUSTRY | 1 | Dec 6, 2023 | clinicaltrials |
| NCT01897454 | Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer | terminated | Phase 2 | 23 | Albert Einstein College of MedicineOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT04637698 | OH2 Oncolytic Viral Therapy in Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 5 | Binhui Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT05580445 | Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 114 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05810792 | Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic Cancer(PANCEP-1) | not yet recruiting | Phase 2 | 50 | Sahlgrenska University HospitalOTHER | 0 | Nov 22, 2023 | clinicaltrials |
| NCT06134765 | Bemalenograstim Alfa for the Prevention in Patients With Colorectal Cancer/Pancreatic Cancer | unknown | Phase 2 | 89 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT02527434 | Study of Tremelimumab in Patients With Advanced Solid Tumors | completed | Phase 2 | 64 | AstraZenecaINDUSTRY | 5 | Nov 15, 2023 | clinicaltrials |
| NCT04565327 | Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma | terminated | Phase 2 | 7 | Zhen Wang, MDOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT03649321 | Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 9 | University of Texas Southwestern Medical CenterOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT02178436 | Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 15 | Mohammed Najeeb Al HallakOTHER | 1 | Nov 7, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Apr 17, 2024source: clinicaltrials